Bradycardia in a pediatric population after sugammadex administration: case series
Erica Viviana Guimarães Carvalho, Sandra Maria Carvalho Caldas, Dinis Fernando Pereira Pinheiro Machado da Costa, Cristina Maria Graça Peixoto Gomes
Sugammadex is a distinctive neuromuscular reversal drug that acts by encapsulating the neuromuscular relaxant molecule and dislodging it from its site of action. Sugammadex has
been approved for pediatric patients over 2 years of age. Although arrhythmias have been reported, there is no report of adverse effects in healthy children, such as severe bradycardia requiring intervention. We report two cases of severe bradycardia immediately after the administration of sugammadex in healthy children. Our aim is to alert to the occurrence of one of the most severe adverse effects of sugammadex, in the healthy pediatric population as well.
1. Naguib M. Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth Analg. 2007;104:575−8.
2. Bridion (sugammadex) [prescribing information]. Whitehouse Station, NJ; Merck & Co, Inc: December 2015.
3. Hunter JM, Naguib M. Sugammadex-induced bradycardia, and asystole: how great is the risk? Br J Anaesth. 2018;121:8−12.
4. Alsuhebani M, Sims T, Hansen JK, et al. Heart rate changes following the administration of sugammadex in children: a prospective, observational study. J Anesth. 2020;34:238−42.